This is a demo store. No orders will be fulfilled.

Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 19 Jan 2012  |  Global

    Advances in Pharmacovigilance Techniques--Technology Benchmarking and Stakeholder Analysis (Technical Insights)

    A Drug Safety Toolkit Moving toward Improved Drug Safety Systems

    Pharmacovigilance activities revolve around ensuring drug safety and preventing adverse drug reactions. While post marketing studies form the core of pharmacovigilance, inclusion of safety measures during clinical development and carrying out additional post marketing active surveillance is being utilized by a number of pharma companies.  Risks ...

    $4,950.00